Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Apellis Pharmaceuticals Inc (APLS)

Apellis Pharmaceuticals Inc (APLS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,077,322
  • Shares Outstanding, K 106,522
  • Annual Sales, $ 66,560 K
  • Annual Income, $ -746,350 K
  • 60-Month Beta 1.54
  • Price/Sales 106.11
  • Price/Cash Flow N/A
  • Price/Book 20.48
Trade APLS with:

Options Overview Details

View History
  • Implied Volatility 73.04% ( -0.10%)
  • Historical Volatility 59.08%
  • IV Percentile 61%
  • IV Rank 6.71%
  • IV High 292.34% on 09/07/21
  • IV Low 57.26% on 10/20/21
  • Put/Call Vol Ratio 20.64
  • Today's Volume 844
  • Volume Avg (30-Day) 1,312
  • Put/Call OI Ratio 1.16
  • Today's Open Interest 32,658
  • Open Int (30-Day) 24,573

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -1.34
  • Number of Estimates 9
  • High Estimate -1.23
  • Low Estimate -1.60
  • Prior Year -2.28
  • Growth Rate Est. (year over year) +41.23%

Price Performance

See More
Period Period Low Period High Performance
1-Month
44.07 +49.54%
on 07/18/22
67.40 -2.23%
on 08/11/22
+19.22 (+41.17%)
since 07/11/22
3-Month
34.09 +93.31%
on 05/12/22
67.40 -2.23%
on 08/11/22
+30.83 (+87.91%)
since 05/11/22
52-Week
27.50 +139.64%
on 09/10/21
67.74 -2.72%
on 08/30/21
+7.90 (+13.62%)
since 08/11/21

Most Recent Stories

More News
Apellis (APLS) Q2 Earnings and Sales Miss Estimates, Stock Down

Apellis' (APLS) missed earnings and sales estimates in the second quarter of 2022. Consequently, the stock declines.

AZN : 64.67 (-2.46%)
NVAX : 40.28 (-2.61%)
BEAM : 66.02 (+0.44%)
APLS : 65.38 (-1.60%)
Apellis Pharmaceuticals, Inc. (APLS) Reports Q2 Loss, Misses Revenue Estimates

Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -2.10% and 4.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...

APLS : 65.38 (-1.60%)
VBLT : 0.2500 (-3.85%)
Apellis Pharmaceuticals Reports Second Quarter 2022 Financial Results

Received U.S. FDA filing acceptance of NDA with Priority Review designation for intravitreal pegcetacoplan for treatment of geographic atrophy; PDUFA...

APLS : 65.38 (-1.60%)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in...

APLS : 65.38 (-1.60%)
Inovio Pharmaceuticals (INO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Inovio (INO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

INO : 2.46 (-5.38%)
APLS : 65.38 (-1.60%)
Apellis Pharmaceuticals to Host Conference Call on Aug 8, 2022 to Discuss Second Quarter 2022 Financial Results

WALTHAM, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in...

APLS : 65.38 (-1.60%)
Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Apellis Pharmaceuticals, Inc. (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

APLS : 65.38 (-1.60%)
TECH : 374.26 (-1.50%)
Apellis' (APLS) Geographic Atrophy NDA Gets Priority Review

The FDA accepts Apellis' (APLS) NDA for pegcetacoplan under a priority review for treating geographic atrophy secondary to age-related macular degeneration. A decision is due on Nov 26, 2022.

CLDX : 34.45 (-7.69%)
BEAM : 66.02 (+0.44%)
ANIK : 21.76 (-5.39%)
APLS : 65.38 (-1.60%)
Biotech Stock Roundup: APLS, NVAX Gain on Updates, INCYs Regulatory News & More

'Regulatory and other updates from Apellis (APLS) and Novavax (NAVX) are a few key highlights from the biotech sector during the past week.

INCY : 73.82 (-0.42%)
NVAX : 40.28 (-2.61%)
APLS : 65.38 (-1.60%)
NEXI : 1.2500 (+1.63%)
Apellis Pharmaceuticals, Inc. (APLS) Moves 16.3% Higher: Will This Strength Last?

Apellis Pharmaceuticals, Inc. (APLS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could...

APLS : 65.38 (-1.60%)
PGEN : 2.33 (-3.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Apellis Pharmaceuticals, Inc. is a clinical-stage biotech focused on the development of novel therapeutics, which work through the inhibition of the complement system, specially targeting the C3 protein of the complement system to treat autoimmune and inflammatory diseases.

See More

Key Turning Points

3rd Resistance Point 69.40
2nd Resistance Point 67.99
1st Resistance Point 67.22
Last Price 65.38
1st Support Level 65.04
2nd Support Level 63.63
3rd Support Level 62.86

See More

52-Week High 67.74
Last Price 65.38
Fibonacci 61.8% 52.37
Fibonacci 50% 47.62
Fibonacci 38.2% 42.87
52-Week Low 27.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar